• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Takeda Research Investment

edit

Takeda Research Investment (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI started operations in November 2001. Their aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

Milestones

edit

• 
  Takeda Research Investment invested in Lectus Therapeutics. (2/13/06)
  Posted 4/22/10 at 7:04pm via lectustherapeutics.com
• 
  Takeda Research Investment invested in Symphogen. (1/10/06)
  Posted 4/20/10 at 7:35pm via sciencebusiness.net

Investments

Videos

Sources

1. Lectus Therapeutics closes Series A funding round raising £8.2 million (lectustherapeutics.com) [edit]
2. Symphogen gets $25M for clinical trials for bleeding treatment (bulletin.sciencebusiness.net) [edit]